Company intelligence / Profile preview

GlycoMar

Oban, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Polysaccharide and glycosaminoglycan products isolated from marine microalgae show strong preclinical anti-inflammatory activity, particularly targeting respiratory diseases in collaboration with pharma partners; their commercial ingredients are marketed for joint, skin, and eye care

Therapeutic areas: CardiovascularImmunologyOphthalmologyRheumatologyPulmonologyInfectious DiseasesDermatologyOncology
Modalities: PolysaccharideGlycosaminoglycanSmall molecule (by extension from saccharide derivatives)
Industry: Biotech

Partnerships

MicroA (scale-up and market ingredient Prasinoguard in cosmetics)Various pharma partners (confidential; anti-inflammatory drug development)

Beyond the preview

Go deeper on GlycoMar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoMar.

Explore the full profile